ABI-007 (Nab-Paclitaxel) and Gemcitabine in Treating Women With Metastatic Breast Cancer
NCT00110084
Completed
RATIONALE: Drugs used in chemotherapy, such as ABI-007(Nab-Paclitaxel((Nanoparticle Albumin Bound)-Paclitaxel)) and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving ABI-007 together with gemcitabine works in treating women with metastatic breast cancer.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/31/2011
Locations: Cancer Center of Kansas, P.A. - Chanute, Chanute, Kansas +15 locations
Conditions: Breast Cancer
Register for Updates
A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC
NCT00343291
Completed
The primary objective of this study will be to determine the progression free survival of patients with stage IIIb/IV non-small cell lung cancer (NSCLC) treated with dual agent monoclonal antibody therapy consisting of cetuximab and bevacizumab in combination with two different regimens of paclitaxel and carboplatin chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2011
Locations: For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wichita, Kansas
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Randomized Trial Evaluating Slow-Release Formulation TAXUS Paclitaxel-Eluting Coronary Stents to Treat De Novo Coronary Lesions
NCT00301522
Completed
The primary objective of this study is to further evaluate the safety and effectiveness of the TAXUS Express2 Paclitaxel-Eluting Coronary Stent System in long lesion lengths, small and large vessel diameters and with multiple overlapping stents in the treatment of de novo coronary artery lesions
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/05/2010
Locations: Shawnee Mission Medical Center, Shawnee Mission, Kansas
Conditions: Coronary Stenosis
Register for Updates
Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC)
NCT00087802
Completed
The purpose of this study is to compare combination treatment of gemcitabine + oxaliplatin (GEMOX) with carboplatin + paclitaxel (CP) to determine if there is a difference in response and safety between the two drug combinations for the treatment of advanced non-small cell lung cancer (NSCLC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/15/2009
Locations: Kansas City Oncology and Hematology Group, Overland Park, Kansas
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
TAXUS ARRIVE 2: A Multi-Center Safety Surveillance Program
NCT00569751
Completed
The TAXUS ARRIVE 2 study is a multi-center safety and surveillance study designed to to compile safety surveillance and clinical outcomes data for the TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System in routine clinical practice and to identify low frequency TAXUS related clinical events.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/25/2008
Locations: University of Kansas Hospital, Kansas City, Kansas
Conditions: Cardiovascular Disease, de Novo Coronary Lesions
Register for Updates
A Study Using Intravenous Paxceed™ to Treat Patients With Rheumatoid Arthritis
NCT00055133
Completed
Paxceed™ is being developed by Angiotech Pharmaceuticals, Inc. for the treatment of Rheumatoid Arthritis (RA). The main objective of this study is to determine the effectiveness of treatment with Paxceed™ in patients with RA. In RA, there is an increase in cell growth and changes in cell function. The active substance in Paxceed™, paclitaxel, has undergone clinical studies as a cancer chemotherapeutic agent and has demonstrated its usefulness as an agent that stops growth of cells and blocks cer... Read More
Gender:
ALL
Ages:
Between 21 years and 70 years
Trial Updated:
07/26/2008
Locations: Arthritis & Rheumatology Clinic of Kansas, Wichita, Kansas
Conditions: Rheumatoid Arthritis
Register for Updates